At a glance

Throughout the coronavirus pandemic, our experts have responded and shared the latest evidence-based safety advice nationally and internationally in the care of pregnant mothers and newborns. From co-authoring COVID-19 guidelines to establishing protocols, our experts have been on the frontline providing insights on how to safely deliver care for those with and without the virus.

This past year we were recognized by the National Safe Sleep Hospital Certification Program as a gold safe sleep champion for our commitment to best practices and education on infant safe sleep.

We unveiled our new pediatric emergency waiting room, a private, family-friendly space to accommodate the needs of families who require trauma and emergency care.

Last October, our surgeons took part in our hospital’s first-ever separation of nine-month-old craniopagus twins. After 10 months of high-tech preparation, the 24 hour landmark surgery was conducted by a multidisciplinary team of more than 30 experts in our state-of-the-art level I Children’s Surgery Center.

Our Comprehensive Epilepsy Program earned accreditation as a level 4 epilepsy center, the highest rating awarded by the National Association of Epilepsy Centers (NAEC). The program provides more complex forms of neurodiagnostic monitoring, medical neuropsychological and psychosocial treatment.

In 2020, we earned the highly prestigious Baby-Friendly designation by Baby-Friendly USA, demonstrating adherence to the highest standards of breastfeeding care built on evidence-based practices recommended by the World Health Organization and the United Nations International Children’s Emergency Fund.

UC Davis Children’s Hospital worked with Our Little Life Foundation and Sacramento County Health Center to establish a Comprehensive Integration of Resilience into Child Life Experiences (CIRCLE) clinic to address the effects of Adverse Childhood Experiences (ACEs) in foster-care children.

UC Davis Health became the first and only hospital in California to offer Zulresso (brexanolone), a new medication to treat mothers with postpartum depression. The 60-hour intravenous treatment has helped new mothers improve their postpartum depression symptoms, including insomnia, appetite loss and mood swings.